Faced with the total failure of its lead pipeline project, Toca 511/Toca FC (vocimagene amiretrorepvec), in its first late-stage trial, Tocagen Inc. is taking the loss on its chin. The San Diego biotech assured investors that it has confidence in the product and will review the data thoroughly, but it is also considering “all options” for the future.
Tocagen reported 12 September that Toca 511/Toca FC – a combination therapy comprising an injectable retroviral replicating vector and an oral extended-release version of 5-fluorocytosine (5-FC) – did not show any meaningful difference compared to bevacizumab-based standard of care on overall survival or any of the secondary endpoints in the Phase III portion of the Phase II/III TOCA 5 trial in high-grade glioma
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?